FRIDAY, OCTOBER 4
OPENING CEREMONY
8.30 – 9.00
GENERAL SESSIONS
- S01. Clinical staging in multimodality treatment 9.00 – 10.00
Chair: Carlos Garcia Carrasco, Giovanni de Manzoni, Hans-Joachim Meyer
– Radiological staging and re-staging of advanced GC – Maria Antonietta Mazzei
– Staging laparoscopy: looking for a standard technique and indications – Ines Goeckel
– European Delphi study on staging laparoscopy – Bas Wjinhoven
– Best Abstract
Discussants: TBD
- S02. High technology in gastric cancer 10.00 – 11.30
Chair: Wojciech Kielan, Magnus Nilsson, Franco Roviello
– Robotic approach and new platforms: 1) UGIRA project – Richard Van Hillegersberg; 2) Hugo, Versius – Simone Giacopuzzi; 3) Hinotori – Franco Roviello
– Best Abstract
Discussants: TBD
BREAK
CLINICAL SESSIONS – NON CARDIA GC
- S03. Treatment of clinical stages I/II 11.45 – 13.15
Chair: Henk Hartgrink, Riccardo Rosati, Shaun Preston
– Organ-sparring surgery – Han-Kwang Yang
– Minimally-invasive surgery (MIS) in complex locations – Suzanne Gisbertz
– Stage II: up-front surgery vs. neo-adjuvant approach – Guillaume Piessen
– Tailored lymphadenectomy in clinical stages I/II – Takeshi Sano
– Best Abstract
Discussants: TBD
Lunch symposium, Poster walk
- S04. Locally-advanced gastric cancer 14.15 – 16.00
Chair: Daniele Marrelli, Paulo Matos da Costa, Katja Ott
– Surgical approach and oncological criteria after neo-adjuvant treatment – Vivian Strong
– Extended lymphadenectomy beyond the D2 – Masanori Terashima
– Pathological and molecular predictors of response to NAC – Heike Grabsch
– Therapeutic approach to elderly or “unfit” patients – Nainika Menon
– Turkish experience on locally advanced gastric cancer – TBD
– Best Abstract
– Invited Commentary. What could neo-adjuvant therapy add to an optimally performed up-front surgery for locally-advanced gastric cancer? – Mitsuru Sasako
Discussants: TBD
BREAK
- L01. Lecture. 16.15 – 16.30
Chair: Luca Saragoni
Molecular biology: a revolution for clinical approach to gastric cancer – Fatima Carneiro
- S05.Metastatic gastric cancer 16.30 – 18.30
Chair: Paulo Kassab, Piotr Kolodziejczyk, Paolo Morgagni, Takeshi Sano
– The role of surgery in oligometastatic gastric cancer: results of the Renaissance trial – Stefan Monig
– Peritoneal-directed treatment for GC peritoneal metastases – Joanna Van Sandick
– Treatment of “converted” metastatic GC – Osvaldo Prado Castro
– How long treatment in stage IV GC? – TBD
– The role of immunotherapy in multimodal approach – Filippo Pietrantonio
– The role of PIPAC in peritoneal metastases from GC – Mickael Chevallay
– Best Abstract
Discussants: TBD
– Consensus: Oligometastatic gastric cancer
1) Question: What can be considered as oligometastatic after oncologic treatment and resection? a single Metastatic site? or a single M+ site and 1 lymph nodal M+ site? or otherwise multiple M+ sites?
– Considerations on survival rates from patient’s database collected by Japanese CONVO – Masanori Terashima(5 min)
– Dutch OMEC – Richard Van Hillegersberg (5 min)
– German FLOT5/RENAISSANCE – Stefan Monig (5 min)
– Italian METAGASTRO – Guido Tiberio (5 min)
– Considerations from the oncologic point of view. TBD (5 min )
– Discussion (10 min) Thortsen Goetze, Filippo Pietrantonio
